Skip to main content
. 2020 Apr 23;20(1):299–307. doi: 10.3892/ol.2020.11570

Figure 1.

Figure 1.

miR-208b-5p expression level and significance in patients with NSCLC. (A) Relative miR-208b-5p expression level in tumor samples of 62 patients with NSCLC. (B) Relative miR-208b-5p expression level measured by reverse transcription-quantitative PCR in NSCLC and adjacent normal tissues. (C) Relative miR-208b-5p expression level in patients with and without lymphatic metastasis. (D) Relative miR-208b-5p expression level in patients with early or advanced stages. (E and F) 5-year overall survival and disease-free survival accessed via the Kaplan-Meier method in patients with NSCLS according to their expression level of miR-208b-5p. *P<0.05 and ***P<0.001. miR, microRNA; NSCLC, non-small cell lung cancer; TNM, Tumor-Node-Metastasis.